Indo Rama Synthetics (India) Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: November 6, 2025, 9:08 pm

Competitors of Indo Rama Synthetics (India) Ltd

All Competitor Stocks of Indo Rama Synthetics (India) Ltd

Quarterly Result

Last Updated: August 20, 2025, 9:10 am

Below is a detailed analysis of the quarterly data for Indo Rama Synthetics (India) Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 1,306.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,198.00 Cr. (Mar 2025) to 1,306.00 Cr., marking an increase of 108.00 Cr..
• For Expenses, as of Jun 2025, the value is 1,215.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,116.00 Cr. (Mar 2025) to 1,215.00 Cr., marking an increase of 99.00 Cr..
• For Operating Profit, as of Jun 2025, the value is 91.00 Cr.. The value appears strong and on an upward trend. It has increased from 82.00 Cr. (Mar 2025) to 91.00 Cr., marking an increase of 9.00 Cr..
• For OPM %, as of Jun 2025, the value is 7.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 7.00%.
• For Other Income, as of Jun 2025, the value is 3.00 Cr.. The value appears to be declining and may need further review. It has decreased from 23.00 Cr. (Mar 2025) to 3.00 Cr., marking a decrease of 20.00 Cr..
• For Interest, as of Jun 2025, the value is 29.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 42.00 Cr. (Mar 2025) to 29.00 Cr., marking a decrease of 13.00 Cr..
• For Depreciation, as of Jun 2025, the value is 12.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 12.00 Cr..
• For Profit before tax, as of Jun 2025, the value is 53.00 Cr.. The value appears strong and on an upward trend. It has increased from 51.00 Cr. (Mar 2025) to 53.00 Cr., marking an increase of 2.00 Cr..
• For Tax %, as of Jun 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00%.
• For Net Profit, as of Jun 2025, the value is 53.00 Cr.. The value appears strong and on an upward trend. It has increased from 51.00 Cr. (Mar 2025) to 53.00 Cr., marking an increase of 2.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is 2.02. The value appears strong and on an upward trend. It has increased from 1.96 (Mar 2025) to 2.02, marking an increase of 0.06.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: October 15, 2025, 5:08 am

Growth

Last Updated: September 5, 2025, 7:25 am

Balance Sheet

Last Updated: July 25, 2025, 3:01 pm

Below is a detailed analysis of the balance sheet data for Indo Rama Synthetics (India) Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 261.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 261.00 Cr..
• For Reserves, as of Mar 2025, the value is 107.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 107.00 Cr..
• For Borrowings, as of Mar 2025, the value is 1,136.00 Cr.. The value appears to be improving (decreasing). However, Borrowings exceed Reserves, which may signal higher financial risk. It has decreased from 1,339.00 Cr. (Mar 2024) to 1,136.00 Cr., marking a decrease of 203.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 1,431.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,199.00 Cr. (Mar 2024) to 1,431.00 Cr., marking an increase of 232.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 2,936.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2,907.00 Cr. (Mar 2024) to 2,936.00 Cr., marking an increase of 29.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 1,264.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,217.00 Cr. (Mar 2024) to 1,264.00 Cr., marking an increase of 47.00 Cr..
• For CWIP, as of Mar 2025, the value is 36.00 Cr.. The value appears to be declining and may need further review. It has decreased from 105.00 Cr. (Mar 2024) to 36.00 Cr., marking a decrease of 69.00 Cr..
• For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
• For Other Assets, as of Mar 2025, the value is 1,636.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,584.00 Cr. (Mar 2024) to 1,636.00 Cr., marking an increase of 52.00 Cr..
• For Total Assets, as of Mar 2025, the value is 2,936.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,907.00 Cr. (Mar 2024) to 2,936.00 Cr., marking an increase of 29.00 Cr..

However, the Borrowings (1,136.00 Cr.) are higher than the Reserves (107.00 Cr.), which may signal higher financial risk.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Key Financial Ratios

After reviewing the key financial ratios for Indo Rama Synthetics (India) Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 0.05. This value is below the healthy minimum of 5. It has increased from -7.79 (Mar 24) to 0.05, marking an increase of 7.84.
• For Diluted EPS (Rs.), as of Mar 25, the value is 0.05. This value is below the healthy minimum of 5. It has increased from -7.79 (Mar 24) to 0.05, marking an increase of 7.84.
• For Cash EPS (Rs.), as of Mar 25, the value is 1.90. This value is below the healthy minimum of 3. It has increased from -6.29 (Mar 24) to 1.90, marking an increase of 8.19.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 14.10. There is no change compared to the previous period (Mar 24) which recorded 14.10.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 14.10. There is no change compared to the previous period (Mar 24) which recorded 14.10.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 163.11. It has increased from 148.34 (Mar 24) to 163.11, marking an increase of 14.77.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 7.92. This value is within the healthy range. It has increased from -1.25 (Mar 24) to 7.92, marking an increase of 9.17.
• For PBIT / Share (Rs.), as of Mar 25, the value is 6.08. This value is within the healthy range. It has increased from -2.75 (Mar 24) to 6.08, marking an increase of 8.83.
• For PBT / Share (Rs.), as of Mar 25, the value is 0.05. This value is within the healthy range. It has increased from -7.79 (Mar 24) to 0.05, marking an increase of 7.84.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 0.05. This value is below the healthy minimum of 2. It has increased from -7.79 (Mar 24) to 0.05, marking an increase of 7.84.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 0.05. This value is below the healthy minimum of 2. It has increased from -7.79 (Mar 24) to 0.05, marking an increase of 7.84.
• For PBDIT Margin (%), as of Mar 25, the value is 4.85. This value is below the healthy minimum of 10. It has increased from -0.84 (Mar 24) to 4.85, marking an increase of 5.69.
• For PBIT Margin (%), as of Mar 25, the value is 3.72. This value is below the healthy minimum of 10. It has increased from -1.85 (Mar 24) to 3.72, marking an increase of 5.57.
• For PBT Margin (%), as of Mar 25, the value is 0.03. This value is below the healthy minimum of 10. It has increased from -5.25 (Mar 24) to 0.03, marking an increase of 5.28.
• For Net Profit Margin (%), as of Mar 25, the value is 0.03. This value is below the healthy minimum of 5. It has increased from -5.25 (Mar 24) to 0.03, marking an increase of 5.28.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 0.03. This value is below the healthy minimum of 8. It has increased from -5.25 (Mar 24) to 0.03, marking an increase of 5.28.
• For Return on Networth / Equity (%), as of Mar 25, the value is 0.38. This value is below the healthy minimum of 15. It has increased from -55.26 (Mar 24) to 0.38, marking an increase of 55.64.
• For Return on Capital Employeed (%), as of Mar 25, the value is 20.27. This value is within the healthy range. It has increased from -8.97 (Mar 24) to 20.27, marking an increase of 29.24.
• For Return On Assets (%), as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. It has increased from -6.99 (Mar 24) to 0.04, marking an increase of 7.03.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.97. This value is within the healthy range. It has decreased from 0.99 (Mar 24) to 0.97, marking a decrease of 0.02.
• For Total Debt / Equity (X), as of Mar 25, the value is 3.06. This value exceeds the healthy maximum of 1. It has decreased from 3.58 (Mar 24) to 3.06, marking a decrease of 0.52.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 1.46. It has increased from 1.38 (Mar 24) to 1.46, marking an increase of 0.08.
• For Current Ratio (X), as of Mar 25, the value is 0.62. This value is below the healthy minimum of 1.5. It has increased from 0.60 (Mar 24) to 0.62, marking an increase of 0.02.
• For Quick Ratio (X), as of Mar 25, the value is 0.34. This value is below the healthy minimum of 1. It has increased from 0.32 (Mar 24) to 0.34, marking an increase of 0.02.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 5.42. This value is within the healthy range. It has increased from 4.62 (Mar 24) to 5.42, marking an increase of 0.80.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 1.32. This value is below the healthy minimum of 3. It has increased from -0.24 (Mar 24) to 1.32, marking an increase of 1.56.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.01. This value is below the healthy minimum of 3. It has increased from -0.54 (Mar 24) to 1.01, marking an increase of 1.55.
• For Enterprise Value (Cr.), as of Mar 25, the value is 1,984.69. It has decreased from 2,303.81 (Mar 24) to 1,984.69, marking a decrease of 319.12.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.46. This value is below the healthy minimum of 1. It has decreased from 0.59 (Mar 24) to 0.46, marking a decrease of 0.13.
• For EV / EBITDA (X), as of Mar 25, the value is 9.60. This value is within the healthy range. It has increased from -70.43 (Mar 24) to 9.60, marking an increase of 80.03.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.20. This value is below the healthy minimum of 1. It has decreased from 0.26 (Mar 24) to 0.20, marking a decrease of 0.06.
• For Price / BV (X), as of Mar 25, the value is 2.41. This value is within the healthy range. It has decreased from 2.76 (Mar 24) to 2.41, marking a decrease of 0.35.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.20. This value is below the healthy minimum of 1. It has decreased from 0.26 (Mar 24) to 0.20, marking a decrease of 0.06.
• For EarningsYield, as of Mar 25, the value is 0.00. This value is below the healthy minimum of 5. It has increased from -0.20 (Mar 24) to 0.00, marking an increase of 0.20.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness